New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications
暂无分享,去创建一个
[1] K. Okamoto,et al. Highly Selective Aldose Reductase Inhibitors. Part 2. Optimization of the Aryl Part of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic Acids. , 1997 .
[2] K. Okamoto,et al. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. , 1997, Journal of medicinal chemistry.
[3] N. Abe,et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. , 1997, Japanese journal of pharmacology.
[4] R. Ramasamy,et al. Aldose Reductase Inhibition Protects Diabetic and Nondiabetic Rat Hearts from Ischemic Injury , 1997, Diabetes.
[5] H. G. Vogel. Drug Discovery and Evaluation: Pharmacological Assays , 1997 .
[6] F. Quiocho,et al. Specifically Targeted Modification of Human Aldose Reductase by Physiological Disulfides* , 1996, The Journal of Biological Chemistry.
[7] J. Jez,et al. Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. , 1996, The Journal of biological chemistry.
[8] G. Rastelli,et al. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. , 1996, Journal of medicinal chemistry.
[9] T. Nakano,et al. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase. , 1996, Biochemistry.
[10] E. Niki,et al. Synthesis and aldose reductase-inhibitory activity of imidazopyrroloquinoline esters. , 1996, Chemical & pharmaceutical bulletin.
[11] K. Okamoto,et al. Highly Selective Aldose Reductase Inhibitors. Part 1. 3‐(Arylalkyl)‐2, 4,5‐trioxoimidazolidine‐1‐acetic Acids. , 1996 .
[12] M. Schwartz,et al. Diabetes Complications--Why Is Glucose Potentially Toxic? , 1996, Science.
[13] K. Okamoto,et al. Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. , 1996, Journal of Medicinal Chemistry.
[14] N. Ansari,et al. Semi-quantitation of mRNA by polymerase chain reaction. Levels of oxidative defense enzymes and aldose reductase in rat lenses cultured in hyperglycemic or oxidative medium. , 1996, Research communications in molecular pathology and pharmacology.
[15] C. Lai,et al. Oxidized aldose reductase: in vivo factor not in vitro artifact. , 1996, Archives of biochemistry and biophysics.
[16] J. Lehmann,et al. The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .
[17] R. Eaton,et al. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[18] I. Kubo,et al. Inhibition of aldose reductase by maesanin and related p-benzoquinone derivatives and effects on other enzymes. , 1996, Bioorganic & medicinal chemistry.
[19] P. Kador,et al. Identification of an aldose reductase inhibitor site by affinity labeling. , 1995, Bioorganic & medicinal chemistry.
[20] T. Flynn,et al. Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase. , 1995, Biochimica et biophysica acta.
[21] W. Ward,et al. Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase. , 1995, Biochemical pharmacology.
[22] A. Del Corso,et al. Occurrence of glutathione-modified aldose reductase in oxidatively stressed bovine lens. , 1995, Biochemical and biophysical research communications.
[23] M. Malamas,et al. N-Substituted Spirosuccinimide, Spiropyridazine, Spiroazetidine, and Acetic Acid Aldose Reductase Inhibitors Derived from Isoquinoline-1,3- diones. Part 2. , 1994 .
[24] R. G. Brown,et al. Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus. , 1994, Journal of the American College of Nutrition.
[25] L. Diemel,et al. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. , 1994, Trends in pharmacological sciences.
[26] M. Malamas,et al. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1. , 1994, Journal of medicinal chemistry.
[27] M. Malamas,et al. N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2. , 1994, Journal of medicinal chemistry.
[28] T. Matsui,et al. Novel and potent aldose reductase inhibitors: 4-benzyl- and 4-(benzothiazol-2-ylmethyl)-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-2-ac etic acid derivatives. , 1994, Chemical & pharmaceutical bulletin.
[29] A. Del Corso,et al. Thiol dependent oxidation of enzymes: the last chance against oxidative stress. , 1994, The International journal of biochemistry.
[30] G. Camici,et al. Glutathione dependent modification of bovine lens aldose reductase. , 1994, Experimental eye research.
[31] G. Petsko,et al. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. , 1994, Biochemistry.
[32] G. Petsko,et al. Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. , 1994, Biochemistry.
[33] B. Hulin. New hypoglycaemic agents. , 1994, Progress in medicinal chemistry.
[34] C. Lipinski,et al. A perspective of aldose reductase inhibitors , 1993 .
[35] F A Quiocho,et al. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[37] P. Oates,et al. Aldose reductase inhibitors: recent developments. , 1993, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[38] S. Srivastava,et al. Does sorbinil bind to the substrate binding site of aldose reductase? , 1992, Biochemical pharmacology.
[39] D. Borhani,et al. The crystal structure of the aldose reductase.NADPH binary complex. , 1992, The Journal of biological chemistry.
[40] M. Cotter,et al. Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats , 1992, British journal of pharmacology.
[41] C. Grimshaw. Aldose reductase: model for a new paradigm of enzymic perfection in detoxification catalysts. , 1992, Biochemistry.
[42] A. Bhatnagar,et al. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. , 1992, Biochemical medicine and metabolic biology.
[43] F A Quiocho,et al. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. , 1992, Science.
[44] C. Lipinski,et al. Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.
[45] B. Mylari,et al. Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives. , 1992, Journal of medicinal chemistry.
[46] M. Asao,et al. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.
[47] T. Flynn,et al. Studies on pig muscle aldose reductase. Kinetic mechanism and evidence for a slow conformational change upon coenzyme binding. , 1992, The Journal of biological chemistry.
[48] B. Mylari,et al. Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain. , 1992, Journal of medicinal chemistry.
[49] D. Moras,et al. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase , 1992, Nature.
[50] W. Ward,et al. (2,6-Dimethylphenylsulphonyl)nitromethane: a new structural type of aldose reductase inhibitor which follows biphasic kinetics and uses an allosteric binding site. , 1991, Biochemical pharmacology.
[51] J. Okuda,et al. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil. , 1991, Chemical & pharmaceutical bulletin.
[52] M. K. Sahib,et al. Monoaminoguanidine inhibits aldose reductase. , 1991, Biochemical pharmacology.
[53] C. Lipinski,et al. pKa, Log P and MedChem CLOGP Fragment Values of Acidic Heterocyclic Potential Bioisosteres , 1991 .
[54] B. Mylari,et al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. , 1991, Journal of medicinal chemistry.
[55] C. Grimshaw,et al. Mechanistic basis for nonlinear kinetics of aldehyde reduction catalyzed by aldose reductase. , 1990, Biochemistry.
[56] O. Hayaishi,et al. A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes. , 1989, Experimental eye research.
[57] B. Wermuth,et al. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. , 1989, The Journal of biological chemistry.
[58] R. Sarges. Aldose Reductase Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1989 .
[59] S. Srivastava,et al. Prevention of Sugar-Induced Cataractogenesis in Rats by Butylated Hydroxytoluene , 1988, Diabetes.
[60] P. Kador. The role of aldose reductase in the development of diabetic complications , 1988, Medicinal research reviews.
[61] Christopher A. Lipinski,et al. Medicinal chemistry of aldose reductase inhibitors , 1988, Medicinal research reviews.
[62] R. Poulsom. Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type. , 1987, Biochemical pharmacology.
[63] L. Humber. The medicinal chemistry of aldose reductase inhibitors. , 1987, Progress in medicinal chemistry.
[64] B. Griffin,et al. Characterization of the reduction of 3-acetylpyridine adenine dinucleotide phosphate by benzyl alcohol catalyzed by aldose reductase. , 1986, Archives of biochemistry and biophysics.
[65] N. Sharpless,et al. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. , 1985, Journal of medicinal chemistry.
[66] J. A. Cromlish,et al. Pig muscle aldehyde reductase. Identity of pig muscle aldehyde reductase with pig lens aldose reductase and with the low Km aldehyde reductase of pig brain and pig kidney. , 1983, The Journal of biological chemistry.
[67] K. Inagaki,et al. Affinity purification and glucose specificity of aldose reductase from bovine lens. , 1982, Archives of biochemistry and biophysics.